NEW YORK (Reuters) - Wyeth (WYE.N: Quote, Profile, Research) said on Thursday it will appeal verdicts in an Arkansas trial involving its hormone replacement drugs in which the jury ordered the drugmaker to pay more than $20 million in damages.

An Arkansas jury awarded Donna Scroggin, who blamed the hormone drugs for her breast cancer, $2.75 million in compensatory damages against Wyeth and co-defendant Upjohn. It later awarded $19,360,000 in punitive damages against Wyeth and $7,760,000 against Upjohn.

"There is no basis in fact or law for this award or for the earlier compensatory damage award," Wyeth attorney Lyn Pruitt said. "We are confident in our position on appeal."

Pruitt said Wyeth would pursue several post-trial motions in an effort to overturn the verdicts "and will ultimately appeal the entire case if necessary."

Wyeth is facing more than 5,000 lawsuits from people who claim they were harmed by its Premarin and Prempro hormone replacement drugs, which have been used by millions of women to control the effects of menopause.

The drugmaker has argued that the risks associated with the hormone replacement therapies were clearly communicated to doctors and patients. The drugs are approved by U.S. health regulators and remain on the market.

Of the six other cases that have gone to trial and reached a verdict, four ended in Wyeth victories, one was won by the plaintiff and another was remanded for a new trial.

Four other cases set for trial were dismissed by courts on summary judgment and a dozen other cases have been voluntarily dismissed by the plaintiffs before trial, Wyeth said.

(Reporting by Bill Berkrot, editing by Phil Berlowitz)